3 years ago

All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.

Ana Moreno, Eduardo Malmierca, Ignacio Santos, Encarnación Cruz-Martos, Pablo Ryan, Gabriel Gaspar, María Teresa de Guzmán, María J Téllez, Carlos Barros, José Sanz, Lourdes Dominguez, Juan Berenguer, Luis M Belda, Raquel Monsalvo, Beatriz Alvarez, Juan J González-García, María T Garcia-Benayas, Juan V San Martin, María Antonia Menendez, Luis Gotuzzo, Laura Benitez, Ana Vegas, Rafael Torres-Perea, Juan E Losa, Teresa Aldámiz-Echevarría, Inmaculada Jarrin, María J Calvo, Marisa Montes, Ángela Gil-Martin, Sari Arponen, Regino Serrano
We evaluated treatment outcomes in a prospective registry of HIV/HCV-coinfected patients treated with interferon-free direct-acting antiviral agent (DAA)-based therapy in hospitals from the region of Madrid between November 2014 and August 2016. We assessed sustained viral response (SVR) at 12 weeks after completion of treatment and used multivariable logistic regression to identify predictors of treatment failure. We evaluated 2,369 patients, of whom 59.5% were non-cirrhotic (Non-C), 33.9% had compensated cirrhosis (Co-C), and 6.6% had decompensated cirrhosis (De-C). The predominant HCV genotypes were 1a (40.9%), 4 (22.4%), 1b (15.1%), and 3 (15.0%). Treatment regimens included sofosbuvir (SOF)/ledipasvir (LDV) (61.9%), SOF plus daclatasvir (DCV) (14.6%), dasabuvir plus ombitasvir/paritaprevir/ritonavir (DSV+OBV/PTV/r) (13.2%), and other regimens (10.3%). Ribavirin was used in 30.6% of patients. Less than 1% of patients discontinued therapy owing to adverse events. The frequency of SVR by intention-to-treat analysis was 92.0% (95% confidence interval [CI]: 90.9-93.1%) overall, 93.8% (95%CI: 92.4-95.0%) for Non-C, 91.0% (95%CI: 88.8-92.9%) for Co-C, and 80.8% (95%CI: 73.7-86.6%) for De-C. The factors associated with treatment failure were male sex (adjusted odds ratio [aOR] 1.75; 95%CI 1.14-2.69), Centers for Diseases Control and Prevention (CDC) category C (aOR 1.65; 95%CI 1.12-2.41), a baseline CD4+ T-cell count <200/mm3 (aOR 2.30; 95%CI 1.35-3.92), an HCV RNA load ≥ 800,000 IU/mL (aOR 1.63; 95%CI 1.14-2.36), Co-C (aOR 1.35; 95%CI 0.96-1.89), De-C (aOR 2.92; 95%CI 1.76-4.87), and the use of SOF plus simeprevir, SOF plus ribavirin, and SMV plus DCV. In conclusion, in this large real-world study, DAA-based therapy was safe and highly effective in coinfected patients. Predictors of failure included gender, HIV-related immunosuppression, HCV RNA load, severity of liver disease, and the use of suboptimal DAA-based regimens. This article is protected by copyright. All rights reserved.

Publisher URL: http://doi.org/10.1002/hep.29814

DOI: 10.1002/hep.29814

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.